Welcome to our dedicated page for Ingevity SEC filings (Ticker: NGVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ingevity Corporation (NYSE: NGVT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered context to help interpret them. Ingevity is a specialty materials and chemical manufacturer organized into three segments—Performance Materials, Advanced Polymer Technologies and Performance Chemicals—and its filings document how these businesses are managed, restructured and financed over time.
Investors can use Ingevity’s Form 10-K annual reports and Form 10-Q quarterly reports to review segment information, including sales and EBITDA for Performance Materials (activated carbon), Advanced Polymer Technologies (caprolactone polymers) and Performance Chemicals (specialty chemicals and pavement or road technologies). These reports also describe the applications for Ingevity’s products, such as adhesives, agrochemicals, asphalt paving, certified biodegradable bioplastics, coatings, elastomers, pavement markings, lubricants, oil drilling and automotive components.
Ingevity’s Form 8-K current reports are particularly important for tracking material events that affect NGVT stock. Recent 8-K filings detail the asset purchase agreement and subsequent amendment with Mainstream Pine Products, LLC for the sale of the North Charleston crude tall oil refinery and the majority of the Industrial Specialties product line, the classification of those operations as discontinued, and the completion of the transaction. Other 8-Ks describe leadership transitions in finance and business segments, the completion of a portfolio review and the decision to explore strategic alternatives for the Advanced Polymer Technologies segment and the Performance Chemicals Road Markings business, as well as preliminary earnings announcements.
On this page, AI-generated summaries highlight the key points of each filing, helping users quickly understand what a lengthy 8-K, 10-Q or 10-K means for Ingevity’s portfolio, margins, cash flow and capital allocation. Filings related to stock repurchases, strategic divestitures and executive changes are surfaced so that investors can monitor how the company is reshaping its specialty chemicals and materials portfolio. Users can also review exhibits referenced in 8-Ks, such as asset purchase agreements and recast financial information, to gain deeper insight into the structure and impact of major transactions.
Ingevity Corp director reports routine stock-based compensation. Director Francis David Segal acquired 396 shares of Ingevity common stock on 01/02/2026 at a price of $60.09 per share. Following this transaction, he beneficially owns 6,051 shares of Ingevity common stock in direct ownership.
The reported shares represent vested deferred stock units that were granted under Ingevity’s director compensation programs, where the director elected to receive deferred stock units instead of cash quarterly director fees. These deferred stock units will convert into an equal number of Ingevity common shares when his service on the board ends, in line with the company’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.
Ingevity Corp director reports stock-based compensation transaction
A director of Ingevity Corp reported acquiring 479 shares of the company’s common stock on 01/02/2026 at a price of $60.09 per share. These shares represent vested deferred stock units the director elected to receive instead of quarterly cash director fees, under Ingevity’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. After this transaction, the director beneficially owns 8,779 shares of Ingevity common stock in direct ownership. The deferred stock units will convert into an equal number of common shares when the director’s board service ends.
Ingevity Corporation completed a previously announced transaction to sell substantially all of the assets, rights and certain liabilities of its industrial specialties product line and its North Charleston, South Carolina crude tall oil refinery to Mainstream Pine Products, LLC as of January 1, 2026.
At closing, the parties signed an amendment to their Asset Purchase Agreement that narrows the deal by excluding non-lignin dispersant products sold to existing customers for agricultural chemical applications, while leaving the rest of the agreement in full force and effect.
Ingevity later issued a press release on January 5, 2026 confirming completion of the transaction, highlighting a significant reshaping of the company’s portfolio around businesses that remain outside the divested industrial specialties and crude tall oil refinery operations.
Ingevity Corp senior vice president of operations Clarence Reid Clontz, Jr. reported his beneficial ownership in the company as of the stated event date. He directly holds 7,029 shares of common stock.
He also holds employee stock options granted under the Ingevity Corporation 2016 Omnibus Incentive Plan. These options cover 217 shares at $53.11 per share that vested in full on February 27, 2020, 496 shares at $74.91 per share that vested in full on February 28, 2021, and 351 shares at $115.22 per share that vested in three equal installments between February 28, 2020 and February 28, 2022.
Ingevity Corporation reported upcoming leadership changes in its finance and operations teams. The company announced that Executive Vice President and Chief Financial Officer Mary Dean Hall will transition out of her CFO role effective May 1, 2026, and then serve in an advisory capacity for one year to support continuity.
Phillip J. Platt, currently Senior Vice President, Finance and Chief Accounting Officer, has been appointed to succeed her as Senior Vice President and Chief Financial Officer and will join the executive leadership team on May 1, 2026. Platt has been with Ingevity since 2015 in multiple senior finance roles, including leading implementation of the global ERP system and overseeing financial reporting, treasury, investor relations, and business transformation.
The company also disclosed that Richard White, Senior Vice President and President, Performance Chemicals, will depart on May 1, 2026 after moving to a special projects role beginning January 1, 2026. A related press release also announced the appointment of Clarence Reid Clontz, Jr. as Senior Vice President, Operations.
Ingevity Corporation reported that it has completed its previously announced portfolio review and is exploring strategic alternatives for its Advanced Polymer Technologies segment and its Performance Chemicals Road Markings business. This means the company is formally assessing options such as potential sales, partnerships, or other structural changes for these operations.
The company also stated that, as part of its efforts to return meaningful capital to stockholders, it has completed over $30 million in stock repurchases during the fourth quarter of 2025. These buybacks reduce the number of shares in the market and represent a direct way of returning cash to shareholders.
Ingevity Corporation is updating how it reports its results to reflect a planned divestiture of major businesses. The company has an Asset Purchase Agreement with Mainstream Pine Products, LLC for the sale of substantially all assets and certain liabilities of its industrial specialties product line (excluding specified products and businesses) and its North Charleston, South Carolina crude tall oil refinery, with closing expected by early 2026.
Ingevity determined that these operations meet the criteria to be classified as held for sale and that the divestiture represents a strategic shift that will have a major effect on its operations and results. As a result, the industrial specialties product line and the refinery are now presented as discontinued operations for all periods shown. Ingevity is furnishing unaudited recast condensed consolidated statements of operations, segment operating results, and certain non-GAAP financial measures for full-year 2024 and 2023 and multiple 2024–2025 quarters, which apply these changes retrospectively and are described as preliminary.
Ingevity Corp (NGVT) insider filing reports no beneficial ownership. A company officer, identified as the Senior Vice President and President of Performance Materials, filed an initial ownership report on Form 3 as of 11/10/2025. The filing states that no securities are beneficially owned by the reporting person at this time. The form is submitted as an individual filing and includes a power of attorney authorizing an attorney-in-fact to sign on the reporting person’s behalf.
Ingevity Corporation (NGVT) reported steady Q3 2025 results. Net sales were $333.1 million versus $333.8 million a year ago, and gross profit rose to $133.9 million from $131.6 million. Income from continuing operations before taxes was $62.2 million (vs. $54.0 million), with net income of $43.5 million. Diluted EPS was $1.18 versus $(2.94), reflecting a large discontinued-operations loss in the prior year. The effective tax rate was 34.4%.
Year‑to‑date, net sales were $912.5 million (vs. $936.8 million) and net loss was $(82.5) million, driven by a non‑cash $183.8 million goodwill impairment in Advanced Polymer Technologies. Operating cash flow improved to $234.1 million (vs. $64.1 million). Total debt including finance leases declined to $1.2639 billion from $1.4052 billion, and interest expense fell to $56.4 million (vs. $69.3 million). Revolver covenants remained comfortable, with net leverage at 2.7x and interest coverage at 5.5x.
The company signed an Asset Purchase Agreement on September 3, 2025 to divest its industrial specialties product line and North Charleston CTO refinery, which are presented as discontinued operations; closing is expected by early 2026. During Q3, NGVT repurchased $25.2 million of stock, or 445,724 shares at a weighted average of $56.09.
Ingevity Corporation furnished preliminary financial results for the three and nine months ended September 30, 2025. The details are provided in a press release attached as Exhibit 99.1, dated November 5, 2025. The information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under the Securities Exchange Act. Additional materials may be available on Ingevity’s investor relations website.